HLB Pharmaceutical Financials
047920 Stock | KRW 23,400 700.00 2.90% |
HLB |
Understanding current and past HLB Pharmaceutical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of HLB Pharmaceutical's financial statements are interrelated, with each one affecting the others. For example, an increase in HLB Pharmaceutical's assets may result in an increase in income on the income statement.
Please note, the presentation of HLB Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HLB Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HLB Pharmaceutical's management manipulating its earnings.
HLB Pharmaceutical Stock Summary
HLB Pharmaceutical competes with Kolon Life, Aminologics CoLtd, Withuspharmaceutical, and High Tech. HLB Pharmaceutical Co., Ltd, a pharmaceutical company, develops peptide drugs in South Korea. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju, South Korea. HLBPHARMA is traded on Korean Securities Dealers Automated Quotations in South Korea.Instrument | Korea Stock View All |
Exchange | KOSDAQ |
ISIN | KR7047920004 |
Business Address | 778-1 Ilpaedong, Namyangju-Si, |
Sector | Healthcare |
Industry | Pharmaceuticals |
Benchmark | Dow Jones Industrial |
Website | www.c-tri.co.kr |
Phone | 82 411 1500 |
Currency | KRW - South Korean Won |
You should never invest in HLB Pharmaceutical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of HLB Stock, because this is throwing your money away. Analyzing the key information contained in HLB Pharmaceutical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
HLB Pharmaceutical Key Financial Ratios
HLB Pharmaceutical's financial ratios allow both analysts and investors to convert raw data from HLB Pharmaceutical's financial statements into concise, actionable information that can be used to evaluate the performance of HLB Pharmaceutical over time and compare it to other companies across industries.Return On Equity | -11.39 | |||
Return On Asset | 0.0219 | |||
Number Of Employees | 14 | |||
Beta | 1.83 | |||
Z Score | 48.6 |
HLB Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HLB Pharmaceutical's current stock value. Our valuation model uses many indicators to compare HLB Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HLB Pharmaceutical competition to find correlations between indicators driving HLB Pharmaceutical's intrinsic value. More Info.HLB Pharmaceutical Co is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value HLB Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for HLB Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.HLB Pharmaceutical Systematic Risk
HLB Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. HLB Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on HLB Pharmaceutical correlated with the market. If Beta is less than 0 HLB Pharmaceutical generally moves in the opposite direction as compared to the market. If HLB Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one HLB Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of HLB Pharmaceutical is generally in the same direction as the market. If Beta > 1 HLB Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
HLB Pharmaceutical November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of HLB Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of HLB Pharmaceutical Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of HLB Pharmaceutical Co based on widely used predictive technical indicators. In general, we focus on analyzing HLB Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build HLB Pharmaceutical's daily price indicators and compare them against related drivers.
Information Ratio | (0.05) | |||
Maximum Drawdown | 33.52 | |||
Value At Risk | (4.48) | |||
Potential Upside | 6.03 |
Complementary Tools for HLB Stock analysis
When running HLB Pharmaceutical's price analysis, check to measure HLB Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HLB Pharmaceutical is operating at the current time. Most of HLB Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of HLB Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HLB Pharmaceutical's price. Additionally, you may evaluate how the addition of HLB Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |